Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro™ (tirzepatide) injection Right
  4. Tirzepatide: Use in Patients With Hypothyroidism or Hyperthyroidism
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Tirzepatide: Use in Patients With Hypothyroidism or Hyperthyroidism

Tirzepatide has not been studied in patients with hypothyroidism or hyperthyroidism.

US_cFAQ_TZP028_HYPOTHYROIDISM_HYPERTHYROIDISM
cFAQ
cFAQ
US_cFAQ_TZP028_HYPOTHYROIDISM_HYPERTHYROIDISM
en-US

Detailed Information

There is no information on the use of tirzepatide in people with hypothyroidism or hyperthyroidism because this has not been studied. People with controlled endocrine abnormalities were not excluded from tirzepatide clinical trials. However, patients were excluded if they had a significant, uncontrolled endocrine abnormality (for example, thyrotoxicosis or adrenal crises) in the opinion of the investigator.

Date of Last Review: February 05, 2021

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly